Recent research demonstrates that aptamer-DNAzyme-based metal-nucleic acid frameworks (MNFs) represent a significant advancement in targeted gastric cancer therapy, offering improved stability, synthesis efficiency, and tumor specificity compared to earlier nanomaterial approaches.

Genicore Biotech will be participating in Bio Asia-Taiwan 2025 from July 24 to 27, 2025, at Booth M1129, 4F, Nangang Exhibition Center Hall 1.

Researchers have developed DNA aptamers for detecting atropine and timolol maleate in ocular fluid. This breakthrough addresses the limitations of traditional methods for monitoring these low-concentration eye disease treatments, enabling personalized medicine and improving drug delivery efficacy.